SPHERA FUNDS MANAGEMENT LTD. — 13F Holdings & Portfolio

CIK 1496201 · latest 13F-HR filed 2026-08-14

SPHERA FUNDS MANAGEMENT LTD. manages $766.5M in 13F-reported U.S. long-equity assets across 106 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are TEVA (6.23%), MLYS (5.17%), TSEM (3.68%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 22 new positions, exited 17, added to 46, and trimmed 20.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
4 ITZHAK SADE BUILDING A
29TH FLOOR
TEL AVIV, L3 6777520
Phone
972-3-6845535
Filing Manager
SPHERA FUNDS MANAGEMENT LTD.
TEL AVIV, L3
Signatory
Oshrat Levi
Chief Financial Officer
Loading holdings…
AUM

$766.5M

Long-equity book

Holdings

106

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+22 / −17 / ↑46 / ↓20

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • TEVA PHARMACEUTICAL INDS LTD$16.6M +48.4%
  • CYTOKINETICS INC$16.1M +614.1%
  • BIOMARIN PHARMACEUTICAL INC$10.9M +137.9%
  • CYBIN INC$6.0M +126.1%
  • MAZE THERAPEUTICS INC$5.7M +83.6%
Show all 46 →

Top Trims

  • NOVA LTD-$9.5M -41.0%
  • ORMAT TECHNOLOGIES INC-$4.6M -60.1%
  • BIOCRYST PHARMACEUTICALS INC-$4.0M -48.8%
  • BIOHAVEN LTD-$2.6M -51.3%
  • UPSTREAM BIO INC-$1.7M -52.8%
Show all 20 →

New Positions

  • INSMED INC$12.7M
  • RHYTHM PHARMACEUTICALS INC$8.9M
  • LAM RESEARCH CORP$8.0M
  • APPLIED MATLS INC$8.0M
  • IDEAYA BIOSCIENCES INC$7.3M
Show all 22 →

Exited Positions

  • AMICUS THERAPEUTIC$8.7M
  • CELLEBRITE DI LTD$8.7M
  • APELLIS PHARMACEUTICALS INC$8.6M
  • PALO ALTO NETWORKS INC$8.5M
  • CAMTEK LTD$8.0M
Show all 17 →
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 TEVA PHARMACEUTICAL INDS LTD TEVA 881624209 $47.8M 6.23% 1,410,082 SH
2 MINERALYS THERAPEUTICS INC MLYS 603170101 $39.7M 5.17% 1,469,971 SH
3 TOWER SEMICONDUCTOR LTD TSEM M87915274 $28.2M 3.68% 108,265 SH
4 SPDR SERIES TRUST Put XBI 78464A870 $23.7M 3.10% 150,000 SH
5 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $22.2M 2.89% 1,014,606 SH
6 BIOGEN INC Call BIIB 09062X103 $21.6M 2.82% 100,000 SH
7 BIOGEN INC BIIB 09062X103 $20.9M 2.72% 96,626 SH
8 ULTRAGENYX PHARMACEUTICAL IN RARE 90400D108 $19.6M 2.56% 588,494 SH
9 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $18.8M 2.45% 328,550 SH
10 CYTOKINETICS INC CYTK 23282W605 $18.7M 2.44% 219,987 SH
11 BRIDGEBIO PHARMA INC BBIO 10806X102 $18.3M 2.38% 245,346 SH
12 COGENT BIOSCIENCES INC COGT 19240Q201 $17.8M 2.32% 459,340 SH
13 NOVA LTD NVMI M7516K103 $13.7M 1.78% 25,169 SH
14 INSMED INC INSM 457669307 $12.7M 1.65% 118,800 SH
15 MAZE THERAPEUTICS INC MAZE 578784100 $12.5M 1.63% 417,564 SH
16 ASTRAZENECA PLC AZN G0593M107 $11.9M 1.55% 62,530 SH
17 SANOFI SA SNY 80105N105 $11.5M 1.50% 269,515 SH
18 CYBIN INC HELP 23256X407 $10.7M 1.40% 1,620,753 SH
19 ELI LILLY & CO LLY 532457108 $9.6M 1.26% 8,040 SH
20 MADRIGAL PHARMACEUTICALS INC MDGL 558868105 $9.4M 1.22% 17,419 SH
21 TREVI THERAPEUTICS INC TRVI 89532M101 $9.3M 1.21% 499,029 SH
22 ACADIA PHARMACEUTICALS INC ACAD 004225108 $9.0M 1.18% 356,534 SH
23 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $9.0M 1.17% 240,868 SH
24 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $8.9M 1.16% 80,400 SH
25 CYTOKINETICS INC Call CYTK 23282W605 $8.5M 1.11% 100,000 SH
26 ORIC PHARMACEUTICALS INC ORIC 68622P109 $8.2M 1.06% 752,983 SH
27 LAM RESEARCH CORP LRCX 512807306 $8.0M 1.04% 18,470 SH
28 APPLIED MATLS INC AMAT 038222105 $8.0M 1.04% 11,040 SH
29 TANGO THERAPEUTICS INC TNGX 87583X109 $7.9M 1.04% 254,250 SH
30 NOVARTIS AG NVS 66987V109 $7.8M 1.02% 50,000 SH
31 SOLAREDGE TECHNOLOGIES INC SEDG 83417MAE4 $7.7M 1.01% 4,000,000 SH
32 VOR BIOPHARMA INC VOR 929033207 $7.7M 1.00% 416,417 SH
33 ABBVIE INC ABBV 00287Y109 $7.6M 0.99% 30,256 SH
34 MERCK & CO INC MRK 58933Y105 $7.5M 0.98% 58,600 SH
35 JOHNSON & JOHNSON JNJ 478160104 $7.3M 0.96% 28,831 SH
36 IDEAYA BIOSCIENCES INC IDYA 45166A102 $7.3M 0.95% 196,408 SH
37 IMMATICS N.V IMTX N44445109 $7.3M 0.95% 720,057 SH
38 NUVECTIS PHARMA INC NVCT 67080T108 $7.0M 0.92% 382,945 SH
39 PFIZER INC PFE 717081103 $6.9M 0.90% 286,000 SH
40 HARMONY BIOSCIENCES HLDGS IN HRMY 413197104 $6.4M 0.84% 176,663 SH
41 XENON PHARMACEUTICALS INC XENE 98420N105 $6.3M 0.83% 105,000 SH
42 CLIMB BIO INC CLYM 28658R106 $6.3M 0.82% 483,747 SH
43 ZENAS BIOPHARMA INC ZBIO 98937L105 $5.9M 0.76% 230,834 SH
44 NOVO-NORDISK A S NVO 670100205 $5.8M 0.75% 120,677 SH
45 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $5.7M 0.75% 112,765 SH
46 PRELUDE THERAPEUTICS INC PRLD 74065P101 $5.4M 0.71% 1,019,832 SH
47 GSK PLC GSK 37733W204 $5.3M 0.70% 102,000 SH
48 FORTE BIOSCIENCES INC FBRX 34962G208 $5.3M 0.69% 249,693 SH
49 BIOAGE LABS INC BIOA 09077V100 $5.2M 0.68% 213,671 SH
50 SCHOLAR ROCK HLDG CORP SRRK 80706P103 $5.2M 0.68% 94,265 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $766.5M 106 0001496201-26-000004
2026-03-31 2026-05-15 $629.7M 97 0001496201-26-000003
2025-12-31 2026-02-17 $517.3M 100 0001496201-26-000002
2025-09-30 2025-11-14 $474.1M 115 0001496201-25-000017